Latest News for: death receptor 3

Edit

Non-Small Cell Lung Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by ...

GetNews 21 Mar 2025
INCY) shared the results from the Phase 3 POD1UM-304 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with ...
Edit

Semaglutide reduces brain inflammation and improves memory in an Alzheimer’s model

PsyPost 17 Mar 2025
It belongs to a class of drugs known as glucagon-like peptide-1 receptor agonists, which help regulate blood sugar and appetite ... This suggests that semaglutide may enhance the sensitivity of existing receptors rather than increasing their quantity.
Edit

Bullous Pemphigoid Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, ...

GetNews 12 Mar 2025
Bullous Pemphigoid Drugs Uptake FASENRA (benralizumab) is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils ... DUPIXENT (dupilumab) is a monoclonal antibody targeting the chain of the interleukin (IL)-4 receptor.
  • 1
×